BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA, Willett CG. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011;18:1319-26. [PMID: 21499862 DOI: 10.1245/s10434-011-1630-6] [Cited by in Crossref: 204] [Cited by in F6Publishing: 169] [Article Influence: 20.4] [Reference Citation Analysis]
Number Citing Articles
1 Shaib WL, Sayegh L, Zhang C, Belalcazar A, Ip A, Alese OB, Akce M, Wu C, Qu Y, Maithel SK, Kooby D, Cardona K, Sarmeinto JM, El-Rayes BF. Induction Therapy in Localized Pancreatic Cancer. Pancreas 2019;48:913-9. [PMID: 31268982 DOI: 10.1097/MPA.0000000000001353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Sen N, Falk S, Abrams R. Role of Chemoradiotherapy in the Adjuvant and Neoadjuvant Settings for Resectable Pancreatic Cancer. Clinical Oncology 2014;26:551-9. [DOI: 10.1016/j.clon.2014.06.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
3 Baschnagel A, Shah C, Margolis J, Nadeau L, Stein J, Jury R, Robertson JM. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine. Int J Radiat Oncol Biol Phys 2012;83:e331-5. [PMID: 22420967 DOI: 10.1016/j.ijrobp.2012.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
4 Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, Büchler MW, Werner J. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20:2188-2196. [PMID: 23247983 DOI: 10.1245/s10434-012-2809-1] [Cited by in Crossref: 146] [Cited by in F6Publishing: 127] [Article Influence: 16.2] [Reference Citation Analysis]
5 Bhosale P, Cox V, Faria S, Javadi S, Viswanathan C, Koay E, Tamm E. Genetics of pancreatic cancer and implications for therapy. Abdom Radiol 2018;43:404-14. [DOI: 10.1007/s00261-017-1394-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
6 Bitterman DS, Winter KA, Hong TS, Fuchs CS, Regine WF, Abrams RA, Safran H, Hoffman JP, Benson AB 3rd, Kasunic T, Mulcahy M, Strauss JF, DiPetrillo T, Stella PJ, Chen Y, Plastaras JP, Crane CH. Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. Int J Radiat Oncol Biol Phys. 2021;109:201-211. [PMID: 32858111 DOI: 10.1016/j.ijrobp.2020.08.042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jones OP, Melling JD, Ghaneh P. Adjuvant therapy in pancreatic cancer. World J Gastroenterol 2014;20:14733-46. [PMID: 25356036 DOI: 10.3748/wjg.v20.i40.14733] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
8 Wolfe AR, Williams TM. Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence. Ann Pancreat Cancer 2018;1:26. [PMID: 32656528 DOI: 10.21037/apc.2018.08.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 2012;9:435-444. [PMID: 22733351 DOI: 10.1038/nrgastro.2012.119] [Cited by in Crossref: 139] [Cited by in F6Publishing: 129] [Article Influence: 15.4] [Reference Citation Analysis]
10 Berber B, Sanabria JR, Braun K, Yao M, Ellis RJ, Kunos CA, Sohn J, Machtay M, Teh BS, Huang Z. Emerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer. Expert Rev Anticancer Ther. 2013;13:481-487. [PMID: 23560842 DOI: 10.1586/era.13.19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
11 Evans DB, Wolff RA. Adjuvant Therapy for Pancreatic Cancer: A Logical Strategy in Search of Progress. Ann Surg Oncol 2011;18:1224-8. [DOI: 10.1245/s10434-011-1633-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Ning Z, Zhu Z, Wang H, Zhang C, Xu L, Zhuang L, Yan X, Wang D, Wang P, Meng Z. High-intensity focused ultrasound enhances the effect of bufalin by inducing apoptosis in pancreatic cancer cells. Onco Targets Ther 2019;12:1161-70. [PMID: 30863083 DOI: 10.2147/OTT.S185953] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 Winter JM, Jiang W, Basturk O, Mino-Kenudson M, Fong ZV, Tan WP, Lavu H, Vollmer CM, Furth EE, Haviland D, Klimstra DS, Jarnagin WR, Lillemoe KD, Yeo CJ, Fernandez-Del Castillo C, Allen PJ. Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component): A Multi-institutional Analysis. Ann Surg 2016;263:793-801. [PMID: 26135696 DOI: 10.1097/SLA.0000000000001319] [Cited by in Crossref: 40] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
14 Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M, Andersson R. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016;12:1929-1946. [PMID: 27246628 DOI: 10.2217/fon-2016-0010] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 21.2] [Reference Citation Analysis]
15 Baines A, Martin P, Rorie C. Current and Emerging Targeting Strategies for Treatment of Pancreatic Cancer. Molecular and Cellular Changes in the Cancer Cell. Elsevier; 2016. pp. 277-320. [DOI: 10.1016/bs.pmbts.2016.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
16 Rieser CJ, Narayanan S, Bahary N, Bartlett DL, Lee KK, Paniccia A, Smith K, Zureikat AH. Optimal management of patients with operable pancreatic head cancer: A Markov decision analysis. J Surg Oncol 2021. [PMID: 34231222 DOI: 10.1002/jso.26589] [Reference Citation Analysis]
17 Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017;18. [PMID: 28640192 DOI: 10.3390/ijms18071338] [Cited by in Crossref: 210] [Cited by in F6Publishing: 175] [Article Influence: 52.5] [Reference Citation Analysis]
18 Kooby DA, Gillespie TW, Liu Y, Byrd-Sellers J, Landry J, Bian J, Lipscomb J. Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. Ann Surg Oncol. 2013;20:3634-3642. [PMID: 23771249 DOI: 10.1245/s10434-013-3047-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
19 Perkhofer L, Ettrich TJ, Seufferlein T. Pancreatic Cancer: Progress in Systemic Therapy. Gastrointest Tumors 2014;1:167-79. [PMID: 26672477 DOI: 10.1159/000380785] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
20 McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Pancreatic cancer: Update on immunotherapies and algenpantucel-L. Hum Vaccin Immunother 2016;12:563-75. [PMID: 26619245 DOI: 10.1080/21645515.2015.1093264] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
21 Yegya-Raman N, Shah MM, Grandhi MS, Poplin E, August DA, Kennedy TJ, Malhotra U, Spencer KR, Carpizo DR, Jabbour SK. Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. Ann Pancreat Cancer 2018;1:20. [PMID: 30687847 DOI: 10.21037/apc.2018.07.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
22 Badiyan SN, Molitoris JK, Chuong MD, Regine WF, Kaiser A. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Surg Oncol Clin N Am 2017;26:431-53. [PMID: 28576181 DOI: 10.1016/j.soc.2017.01.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
23 Smaglo BG, Pishvaian MJ. Postresection chemotherapy for pancreatic cancer. Cancer J 2012;18:614-23. [PMID: 23187850 DOI: 10.1097/PPO.0b013e31827459d8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
24 Klaiber U, Leonhardt C, Strobel O, Tjaden C, Hackert T, Neoptolemos JP. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbecks Arch Surg 2018;403:917-32. [DOI: 10.1007/s00423-018-1724-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
25 Oh TG, Chung MJ, Bang S, Park SW, Chung JB, Song SY, Seong J, Kang CM, Lee WJ, Park JY. Validation of group B borderline resectable pancreatic cancer: retrospective analysis. Gut Liver 2014;8:557-62. [PMID: 25228978 DOI: 10.5009/gnl13264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
26 Delitto D, Wallet SM, Hughes SJ. Targeting tumor tolerance: A new hope for pancreatic cancer therapy? Pharmacol Ther. 2016;166:9-29. [PMID: 27343757 DOI: 10.1016/j.pharmthera.2016.06.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
27 Sugumar K, Hue JJ, De La Serna S, Rothermel LD, Ocuin LM, Hardacre JM, Ammori JB, Winter JM. The importance of time-to-adjuvant treatment on survival with pancreatic cancer: A systematic review and meta-analysis. Cancer Rep (Hoboken) 2021;:e1390. [PMID: 34245139 DOI: 10.1002/cnr2.1390] [Reference Citation Analysis]
28 Kim BH, Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Joo I, Ha SW. Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma. Cancer Res Treat 2015;47:274-81. [PMID: 25544574 DOI: 10.4143/crt.2014.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
29 Heestand GM, Kurzrock R. Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget 2015;6:4553-61. [PMID: 25714017 DOI: 10.18632/oncotarget.2972] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 10.2] [Reference Citation Analysis]
30 Herman JM, Thomas CR. RTOG 0529: Intensity Modulated Radiation Therapy and Anal Cancer, a Step in the Right Direction? International Journal of Radiation Oncology*Biology*Physics 2013;86:8-10. [DOI: 10.1016/j.ijrobp.2013.01.034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
31 Sohal DPS, Tullio K, Khorana AA. Do patients with pancreatic body or tail cancer benefit from adjuvant therapy?A cohort study. Surg Oncol 2018;27:245-50. [PMID: 29937178 DOI: 10.1016/j.suronc.2018.05.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
32 Sengul Samanci N, Çelik E, Bagcilar O, Tutar O, Samanci C, Velidedeoglu M, Yassa AE, Demirci NS, Demirelli FH. Use of volumetric CT scanning to predict tumor staging and survival in pancreatic cancer patients that are to be administered curative resection. J Surg Oncol 2021;123:1757-63. [PMID: 33684252 DOI: 10.1002/jso.26455] [Reference Citation Analysis]
33 Goodman KA, Hajj C. Role of radiation therapy in the management of pancreatic cancer. J Surg Oncol. 2013;107:86-96. [PMID: 22532174 DOI: 10.1002/jso.23137] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
34 Hernando-Cubero J, Matos-García I, Alonso-Orduña V, Capdevila J. The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. J Gastrointest Cancer 2017;48:135-47. [PMID: 28397102 DOI: 10.1007/s12029-017-9946-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
35 Lawrence YR, Moughan J, Magliocco AM, Klimowicz AC, Regine WF, Mowat RB, DiPetrillo TA, Small W Jr, Simko JP, Golan T, Winter KA, Guha C, Crane CH, Dicker AP. Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704.Cancer. 2018;124:491-498. [PMID: 29053185 DOI: 10.1002/cncr.31058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Sirohi B, Singh A, Dawood S, Shrikhande SV. Advances in chemotherapy for pancreatic cancer. Indian J Surg Oncol 2015;6:47-56. [PMID: 25937764 DOI: 10.1007/s13193-014-0371-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
37 Goff SL, Chabot JA. A Neoadjuvant Strategy for the Management of Nonmetastatic Pancreatic Cancer. The Cancer Journal 2012;18:602-8. [DOI: 10.1097/ppo.0b013e318279aade] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
38 Seshacharyulu P, Baine MJ, Souchek JJ, Menning M, Kaur S, Yan Y, Ouellette MM, Jain M, Lin C, Batra SK. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta Rev Cancer 2017;1868:69-92. [PMID: 28249796 DOI: 10.1016/j.bbcan.2017.02.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
39 Ng KYY, Chow EWX, Jiang B, Lim C, Goh BKP, Lee SY, Teo JY, Tan DMY, Cheow PC, Ooi LLPJ, Chow PKH, Lee JJX, Kam JH, Koh YX, Jeyaraj PR, Tan EK, Choo SP, Chan CY, Chung AYF, Tai D. Resected pancreatic adenocarcinoma: An Asian institution's experience. Cancer Rep (Hoboken) 2021;:e1393. [PMID: 33939335 DOI: 10.1002/cnr2.1393] [Reference Citation Analysis]
40 Zhu X, Li F, Liu W, Shi D, Ju X, Cao Y, Shen Y, Cao F, Qing S, Fang F, Jia Z, Zhang H. Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matched analysis of a prospectively collected database. Cancer Manag Res 2018;10:1295-304. [PMID: 29872342 DOI: 10.2147/CMAR.S163655] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
41 O’Reilly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M, Tang LH, LaValle J, Winston C, DeMatteo RP. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014;260:142-148. [PMID: 24901360 DOI: 10.1097/sla.0000000000000251] [Cited by in Crossref: 92] [Cited by in F6Publishing: 37] [Article Influence: 13.1] [Reference Citation Analysis]
42 Boyle J, Czito B, Willett C, Palta M. Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. J Gastrointest Oncol 2015;6:436-44. [PMID: 26261730 DOI: 10.3978/j.issn.2078-6891.2015.014] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
43 Boimel PJ, Berman AT, Li J, Apisarnthanarax S, Both S, Lelionis K, Larson GL, Teitelbaum U, Lukens JN, Ben-Josef E, Metz JM, Plastaras JP. Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma. J Gastrointest Oncol 2017;8:665-74. [PMID: 28890817 DOI: 10.21037/jgo.2017.03.04] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
44 Jones WE 3rd, Suh WW, Abdel-Wahab M, Abrams RA, Azad N, Das P, Dragovic J, Goodman KA, Jabbour SK, Konski AA, Koong AC, Kumar R, Lee P, Pawlik TM, Small W Jr, Herman JM; Expert Panel on Radiation OncologyGastrointestinal. ACR Appropriateness Criteria® Resectable Pancreatic Cancer. Am J Clin Oncol 2017;40:109-17. [PMID: 28230650 DOI: 10.1097/COC.0000000000000370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
45 Mukhija D, Sohal DPS, Khorana AA. Adjuvant Treatment in Potentially Curable Pancreatic Cancer: Need to Include Tumor Location in the Equation? Pancreas 2018;47:e50-2. [PMID: 30113430 DOI: 10.1097/MPA.0000000000001125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Donahue TR, Nguyen AH, Moughan J, Li L, Tatishchev S, Toste P, Farrell JJ. Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer. J Surg Oncol. 2014;110:952-959. [PMID: 25132574 DOI: 10.1002/jso.23750] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
47 Osipov A, Blair AB, Liberto J, Wang J, Li K, Herbst B, Xu Y, Li S, Niu N, Rashid R, Ding D, Liu Y, Wang Z, Wolfgang CL, Burkhart RA, Laheru D, Zheng L. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. Cancer Biol Med 2021;18:206-14. [PMID: 33628595 DOI: 10.20892/j.issn.2095-3941.2020.0273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Donahue TR, Reber HA. Surgical management of pancreatic cancer--pancreaticoduodenectomy. Semin Oncol 2015;42:98-109. [PMID: 25726055 DOI: 10.1053/j.seminoncol.2014.12.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
49 Xu JB, Jiang B, Chen Y, Qi FZ, Zhang JH, Yuan H. Optimal adjuvant chemotherapy for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Oncotarget 2017;8:81419-29. [PMID: 29113401 DOI: 10.18632/oncotarget.19082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
50 Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S. Pancreatic Adenocarcinoma: Improving Prevention and Survivorship. American Society of Clinical Oncology Educational Book 2017. [DOI: 10.1200/edbk_175222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
51 Witkowski ER, Smith JK, Tseng JF. Outcomes following resection of pancreatic cancer. J Surg Oncol. 2013;107:97-103. [PMID: 22991309 DOI: 10.1002/jso.23267] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
52 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol. 2014;20:11142-11159. [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 63] [Article Influence: 12.3] [Reference Citation Analysis]
53 Pelzer U, Sinn M, Stieler J, Riess H. [Multimodal treatment of pancreatic cancer]. Internist (Berl). 2014;55:31-36. [PMID: 24399472 DOI: 10.1007/s00108-013-3316-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, Wang HP, Tu YK. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14:1095-1103. [PMID: 24035532 DOI: 10.1016/s1470-2045(13)70388-7] [Cited by in Crossref: 151] [Cited by in F6Publishing: 66] [Article Influence: 18.9] [Reference Citation Analysis]
55 Páez D, Labonte MJ, Lenz HJ. Pancreatic cancer: medical management (novel chemotherapeutics). Gastroenterol Clin North Am. 2012;41:189-209. [PMID: 22341258 DOI: 10.1016/j.gtc.2011.12.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
56 Mcdonald AM, Dulaney CR, López-araujo J, Posey JA, Keene KS, Christein JD, Heslin MJ, Wood TE, Jacob R. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. J Gastrointest Canc 2015;46:149-55. [DOI: 10.1007/s12029-015-9702-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
57 Toyama Y, Yoshida S, Saito R, Kitamura H, Okui N, Miyake R, Ito R, Son K, Usuba T, Nojiri T, Yanaga K. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life. World J Surg Oncol 2013;11:3. [PMID: 23302293 DOI: 10.1186/1477-7819-11-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
58 Strom TJ, Klapman JB, Springett GM, Meredith KL, Hoffe SE, Choi J, Hodul P, Malafa MP, Shridhar R. Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage. Surg Endosc 2015;29:3273-81. [PMID: 25631110 DOI: 10.1007/s00464-015-4075-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
59 Antoniou G, Kountourakis P, Papadimitriou K, Vassiliou V, Papamichael D. Adjuvant therapy for resectable pancreatic adenocarcinoma: Review of the current treatment approaches and future directions. Cancer Treatment Reviews 2014;40:78-85. [DOI: 10.1016/j.ctrv.2013.05.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
60 Myrehaug S, Sahgal A, Russo SM, Lo SS, Rosati LM, Mayr NA, Lock M, Small W Jr, Dorth JA, Ellis RJ, Teh BS, Herman JM. Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions. Expert Rev Anticancer Ther 2016;16:523-30. [PMID: 26999329 DOI: 10.1586/14737140.2016.1168698] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
61 Brunner TB, Seufferlein T. Pancreatic cancer chemoradiotherapy. Best Pract Res Clin Gastroenterol. 2016;30:617-628. [PMID: 27644909 DOI: 10.1016/j.bpg.2016.08.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
62 Fenocchio E, Filippi R, Lombardi P, Quarà V, Milanesio M, Aimar G, Leone F, Aglietta M. Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? Cancers (Basel) 2019;11:E1547. [PMID: 31614884 DOI: 10.3390/cancers11101547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
63 Kelly KJ, Winslow E, Kooby D, Lad NL, Parikh AA, Scoggins CR, Ahmad S, Martin RC, Maithel SK, Kim HJ, Merchant NB, Cho CS, Weber SM. Vein Involvement During Pancreaticoduodenectomy: Is There a Need for Redefinition of “Borderline Resectable Disease”? J Gastrointest Surg 2013;17:1209-17. [DOI: 10.1007/s11605-013-2178-5] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 7.1] [Reference Citation Analysis]
64 Zhang T, Wei L, Yuan G, Zhao D, Zhang M, Zhang G, Wang P. A new delineation method research of the clinical target volume for pancreatic cancer adjuvant radiotherapy. Cancer/Radiothérapie 2019;23:201-8. [DOI: 10.1016/j.canrad.2018.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Chadha AS, Khoo A, Aliru ML, Arora HK, Gunther JR, Krishnan S. Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer. Semin Radiat Oncol 2016;26:320-37. [PMID: 27619253 DOI: 10.1016/j.semradonc.2016.05.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
66 Macchini M, Chiaravalli M, Zanon S, Peretti U, Mazza E, Gianni L, Reni M. Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. Cancer Treat Rev 2019;72:1-6. [PMID: 30414985 DOI: 10.1016/j.ctrv.2018.10.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
67 Hoffe S, Rao N, Shridhar R. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation. Semin Radiat Oncol 2014;24:113-25. [PMID: 24635868 DOI: 10.1016/j.semradonc.2013.11.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
68 Shaib WL, Narayan AS, Switchenko JM, Kane SR, Wu C, Akce M, Alese OB, Patel PR, Maithel SK, Sarmiento JM, Kooby DA, El-Rayes BF. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Cancer 2019;125:57-67. [PMID: 30457666 DOI: 10.1002/cncr.31787] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
69 Askari E, Seyfoori A, Amereh M, Gharaie SS, Ghazali HS, Ghazali ZS, Khunjush B, Akbari M. Stimuli-Responsive Hydrogels for Local Post-Surgical Drug Delivery. Gels 2020;6:E14. [PMID: 32397180 DOI: 10.3390/gels6020014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
70 Kizilbash SH, Ward KC, Liang JJ, Jaiyesimi I, Lipscomb J. Survival outcomes in patients with early stage, resected pancreatic cancer - a comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens. Int J Clin Pract 2014;68:578-89. [PMID: 24472057 DOI: 10.1111/ijcp.12353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
71 Silvestris N, Brunetti O, Vasile E, Cellini F, Cataldo I, Pusceddu V, Cattaneo M, Partelli S, Scartozzi M, Aprile G, Casadei Gardini A, Morganti AG, Valentini V, Scarpa A, Falconi M, Calabrese A, Lorusso V, Reni M, Cascinu S. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Crit Rev Oncol Hematol. 2017;111:152-165. [PMID: 28259290 DOI: 10.1016/j.critrevonc.2017.01.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
72 Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urba S, Zeh HJ, Katz MH. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2541-2556. [PMID: 27247221 DOI: 10.1200/jco.2016.67.5553] [Cited by in Crossref: 195] [Cited by in F6Publishing: 69] [Article Influence: 39.0] [Reference Citation Analysis]
73 Sawicka E, Mirończuk A, Wojtukiewicz MZ, Sierko E. Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question? Contemp Oncol (Pozn) 2016;20:102-8. [PMID: 27358587 DOI: 10.5114/wo.2016.60066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
74 Mills MN, Naz A, Thawani C, Walker C, Figura NB, Kushchayev S, Oliver DE, Etame AB, Yu HM, Robinson TJ, Liu JKC, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Capecitabine and stereotactic radiation in the management of breast cancer brain metastases. BMC Cancer 2021;21:552. [PMID: 33992087 DOI: 10.1186/s12885-021-08302-9] [Reference Citation Analysis]
75 Merrell KW, Haddock MG, Quevedo JF, Harmsen WS, Kendrick ML, Miller RC, Hallemeier CL. Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics 2016;94:561-70. [DOI: 10.1016/j.ijrobp.2015.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
76 Yu Z, Zhong W, Tan ZM, Wang LY, Yuan YH. Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis. Am J Clin Oncol. 2015;38:322-325. [PMID: 23934134 DOI: 10.1097/coc.0b013e3182a46782] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
77 Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Bui JL, Yuan C, Qian ZR, Babic A, Da Silva A, Nowak JA, Khalaf N, Brais LK, Welch MW, Zellers CL, Ng K, Chang DT, Miksad RA, Bullock AJ, Tseng JF, Swanson RS, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Hornick JL, Ogino S, Fuchs CS, Hezel AF, Koong AC, Wolpin BM. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Br J Cancer. 2017;117:1874-1882. [PMID: 28982112 DOI: 10.1038/bjc.2017.349] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
78 Benassai G, Quarto G, Perrotta S, Furino E, Benassai GL, Amato B, Bianco T, De Palma G, Forestieri P. Long-term survival after curative resection for pancreatic ductal adenocarcinoma--Surgical treatment. Int J Surg 2015;21 Suppl 1:S1-3. [PMID: 26118618 DOI: 10.1016/j.ijsu.2015.06.050] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
79 Inoko K, Hiraoka K, Inagaki A, Takahashi M, Kushibiki T, Hontani K, Takano H, Sato S, Takeuchi S, Nakamura T, Tsuchikawa T, Shichinohe T, Gruber HE, Jolly DJ, Kasahara N, Hirano S. Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. Cancer Gene Ther 2018;25:184-95. [PMID: 29735994 DOI: 10.1038/s41417-018-0020-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
80 Zheng R, Wang C, Huang X, Lin Q, Huang D, Li XB, Huang H, Xu B. Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial. BMJ Open 2020;10:e039900. [PMID: 33154057 DOI: 10.1136/bmjopen-2020-039900] [Reference Citation Analysis]
81 Yang A, O'Reilly EM. Novel directions in neoadjuvant therapy for pancreas adenocarcinoma. Expert Rev Gastroenterol Hepatol 2015;9:585-601. [PMID: 25686370 DOI: 10.1586/17474124.2015.1012496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
82 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.1002/caac.21190] [Reference Citation Analysis]
83 Rajagopalan MS, Heron DE, Wegner RE, Zeh HJ, Bahary N, Krasinskas AM, Lembersky B, Brand R, Moser AJ, Quinn AE, Burton SA. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Radiat Oncol 2013;8:254. [PMID: 24175982 DOI: 10.1186/1748-717X-8-254] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 5.1] [Reference Citation Analysis]
84 Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321-337. [PMID: 23814611 DOI: 10.1177/1756283x13478680] [Cited by in Crossref: 155] [Cited by in F6Publishing: 94] [Article Influence: 19.4] [Reference Citation Analysis]
85 Chopra A, Hodges JC, Olson A, Burton S, Ellsworth SG, Bahary N, Singhi AD, Boone BA, Beane JD, Bartlett D, Lee KK, Hogg ME, Lotze MT, Paniccia A, Zeh H, Zureikat AH. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Ann Surg Oncol 2021;28:3779-88. [PMID: 33231769 DOI: 10.1245/s10434-020-09391-9] [Reference Citation Analysis]
86 Liang L, Ding Y, Yu Y, Liu K, Rao S, Ge Y, Zeng M. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study. BMC Med Imaging 2021;21:75. [PMID: 33902469 DOI: 10.1186/s12880-021-00605-4] [Reference Citation Analysis]
87 Roth S, Springfeld C, Diener MK, Tjaden C, Knebel P, Klaiber U, Michalski CW, Mieth M, Jäger D, Büchler MW, Hackert T. Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study. BMJ Open 2019;9:e028696. [PMID: 31434770 DOI: 10.1136/bmjopen-2018-028696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
88 Chuong MD, Boggs DH, Patel KN, Regine WF. Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us? J Gastrointest Oncol. 2014;5:166-177. [PMID: 24982765 DOI: 10.3978/j.issn.2078-6891.2014.025] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
89 Wang F, Kumar P. The role of radiotherapy in management of pancreatic cancer. J Gastrointest Oncol. 2011;2:157-167. [PMID: 22811846 DOI: 10.3978/j.issn.2078-6891.2011.032] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
90 Heinemann V. Treatment of locoregional disease: adjuvant versus neoadjuvant. Annals of Oncology 2012;23:x141-7. [DOI: 10.1093/annonc/mds312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
91 Narang AK, Herman JM. The promise of modern radiotherapy in resected pancreatic adenocarcinoma: a response to Bekaii-Saab et al. Ann Surg Oncol 2014;21:1064-6. [PMID: 24522986 DOI: 10.1245/s10434-013-3344-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
92 Cerullo M, Gani F, Chen SY, Canner JK, Herman JM, Laheru D, Pawlik TM. Assessing the Financial Burden Associated With Treatment Options for Resectable Pancreatic Cancer. Ann Surg 2018;267:544-51. [PMID: 27787294 DOI: 10.1097/SLA.0000000000002069] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
93 Maeda S, Unno M, Yu J. Adjuvant and neoadjuvant therapy for pancreatic cancer. Journal of Pancreatology 2019;2:100-6. [DOI: 10.1097/jp9.0000000000000028] [Cited by in Crossref: 13] [Article Influence: 6.5] [Reference Citation Analysis]
94 Huang L, Balavarca Y, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Zadnik V, Primic-Žakelj M, Mägi M, Grützmann R, Besselink MG, Schrotz-King P, Brenner H, Jansen L. Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study. BMC Med 2019;17:66. [PMID: 30905320 DOI: 10.1186/s12916-019-1304-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
95 Klaiber U, Hackert T, Neoptolemos JP. Adjuvant treatment for pancreatic cancer. Transl Gastroenterol Hepatol 2019;4:27. [PMID: 31143848 DOI: 10.21037/tgh.2019.04.04] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
96 Nichols RC, Huh S, Li Z, Rutenberg M. Proton therapy for pancreatic cancer. World J Gastrointest Oncol 2015;7:141-7. [PMID: 26380057 DOI: 10.4251/wjgo.v7.i9.141] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
97 Du L, DeFoe M, Ruzinova MB, Olsen JR, Wang-Gillam A. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am 2015;29:717-26. [PMID: 26226906 DOI: 10.1016/j.hoc.2015.04.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
98 Kowalchuk RO, Lester SC, Graham RP, Harmsen WS, Zhang L, Halfdanarson TR, Smoot RL, Gits HC, Ma WW, Owen D, Mahipal A, Miller RC, Wittich MAN, Cleary SP, McWilliams RR, Haddock MG, Hallemeier CL, Truty MJ, Merrell KW. Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9. Front Oncol 2021;11:651119. [PMID: 34046346 DOI: 10.3389/fonc.2021.651119] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Winter JM, Jiang W, Basturk O, Mino-Kenudson M, Fong ZV, Tan WP, Lavu H, Vollmer CM, Furth EE, Haviland D, Klimstra DS, Jarnagin WR, Lillemoe KD, Yeo CJ, Fernandez-Del Castillo C, Allen PJ. Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component): A Multi-institutional Analysis. Ann Surg 2016;263:793-801. [PMID: 26135696 DOI: 10.1097/SLA.0000000000001319] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
100 Xie H, Jiang W, Jiang J, Wang Y, Kim R, Liu X, Liu X. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer. 2013;119:173-181. [PMID: 22736490 DOI: 10.1002/cncr.27715] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
101 Chang DS, Bartlett GK, Das IJ, Cardenes HR. Beam angle selection for intensity-modulated radiotherapy (IMRT) treatment of unresectable pancreatic cancer: are noncoplanar beam angles necessary? Clin Transl Oncol 2013;15:720-4. [PMID: 23359183 DOI: 10.1007/s12094-012-0998-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
102 Jin WH, Hoffe SE, Shridhar R, Strom T, Venkat P, Springett GM, Hodul PJ, Pimiento JM, Meredith KL, Malafa MP, Frakes JM. Adjuvant radiation provides survival benefit for resected pancreatic adenocarcinomas of the tail. J Gastrointest Oncol 2018;9:487-94. [PMID: 29998014 DOI: 10.21037/jgo.2018.02.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
103 Winner M, Goff SL, Chabot JA. Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma. Semin Oncol 2015;42:86-97. [PMID: 25726054 DOI: 10.1053/j.seminoncol.2014.12.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
104 Takaori K, Bassi C, Biankin A, Brunner TB, Cataldo I, Campbell F, Cunningham D, Falconi M, Frampton AE, Furuse J, Giovannini M, Jackson R, Nakamura A, Nealon W, Neoptolemos JP, Real FX, Scarpa A, Sclafani F, Windsor JA, Yamaguchi K, Wolfgang C, Johnson CD;  IAP/EPC study group on the clinical managements of pancreatic cancer. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology. 2016;16:14-27. [PMID: 26699808 DOI: 10.1016/j.pan.2015.10.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 7.7] [Reference Citation Analysis]
105 Abrams RA, Winter KA, Safran H, Goodman KA, Regine WF, Berger AC, Gillin MT, Philip PA, Lowy AM, Wu A, DiPetrillo TA, Corn BW, Seaward SA, Haddock MG, Song S, Jiang Y, Fisher BJ, Katz AW, Mehta S, Willett CG, Crane CH. Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial. Am J Clin Oncol 2020;43:173-9. [PMID: 31985516 DOI: 10.1097/COC.0000000000000633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
106 Sultana A, Cox T, Ghaneh P, Neoptolemos JP. Adjuvant therapy for pancreatic cancer. Recent Results Cancer Res. 2012;196:65-88. [PMID: 23129367 DOI: 10.1007/978-3-642-31629-6_5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
107 Kang MJ, Jang J, Kim S. Surgical resection of pancreatic head cancer: What is the optimal extent of surgery? Cancer Letters 2016;382:259-65. [DOI: 10.1016/j.canlet.2016.01.042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
108 Lowery MA, O'Reilly EM. Genomics and pharmacogenomics of pancreatic adenocarcinoma. Pharmacogenomics J 2012;12:1-9. [PMID: 22186617 DOI: 10.1038/tpj.2011.52] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
109 Ma SJ, Hermann GM, Prezzano KM, Serra LM, Iovoli AJ, Singh AK. Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-II pancreatic cancer. Cancer Med 2019;8:939-52. [PMID: 30652417 DOI: 10.1002/cam4.1967] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
110 Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol 2015;21:9297-316. [PMID: 26309356 DOI: 10.3748/wjg.v21.i31.9297] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 68] [Article Influence: 16.4] [Reference Citation Analysis]
111 Nichols RC, Rutenberg M. Optimizing neoadjuvant radiotherapy for resectable and borderline resectable pancreatic cancer using protons. World J Gastrointest Surg. 2019;11:303-307. [PMID: 31602289 DOI: 10.4240/wjgs.v11.i7.303] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
112 Åkerberg D, Björnsson B, Ansari D. Factors influencing receipt of adjuvant chemotherapy after surgery for pancreatic cancer: a two-center retrospective cohort study. Scand J Gastroenterol 2017;52:56-60. [PMID: 27598522 DOI: 10.1080/00365521.2016.1228118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
113 Trakul N, Koong AC, Maxim PG, Chang DT. Modern radiation therapy techniques for pancreatic cancer. Gastroenterol Clin North Am 2012;41:223-35. [PMID: 22341260 DOI: 10.1016/j.gtc.2011.12.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
114 D'Angelo FA, Antolino L, La Rocca M, Petrucciani N, Magistri P, Aurello P, Ramacciato G. Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials. Med Oncol 2016;33:28. [PMID: 26883935 DOI: 10.1007/s12032-016-0742-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
115 Regine WF, Winter K, Abrams RA, Safran H, Kessel IL, Chen Y, Fugazzi JA, Donnelly ED, DiPetrillo TA, Narayan S, Plastaras JP, Gaur R, Delouya G, Suh JH, Meyer JE, Haddock MG, Didolkar MS, Padula GDA, Johnson D, Hoffman JP, Crane CH. Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol 2018;3:154-62. [PMID: 29904740 DOI: 10.1016/j.adro.2018.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
116 Essaji Y, Rocha FG. Seminars in surgical oncology-Pancreas cancer adjuvant therapy trials. J Surg Oncol 2021;123:1467-74. [PMID: 33831255 DOI: 10.1002/jso.26382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Mavros MN, Moris D, Karanicolas PJ, Katz MHG, O'Reilly EM, Pawlik TM. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review. JAMA Surg 2021;156:663-72. [PMID: 33787841 DOI: 10.1001/jamasurg.2021.0149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Wu G, Baine MJ, Zhao N, Li S, Li X, Lin C. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer. BMC Cancer 2019;19:977. [PMID: 31640607 DOI: 10.1186/s12885-019-6220-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
119 Tingstedt B, Andersson B, Jönsson C, Formichov V, Bratlie S, Öhman M, Karlsson B, Ansorge C, Segersvärd R, Gasslander T. First results from the Swedish National Pancreatic and Periampullary Cancer Registry. HPB 2019;21:34-42. [DOI: 10.1016/j.hpb.2018.06.1811] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 9.5] [Reference Citation Analysis]
120 Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44. [PMID: 25935754 DOI: 10.1186/s13045-015-0141-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
121 Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol 2019;16:11-26. [PMID: 30341417 DOI: 10.1038/s41571-018-0112-1] [Cited by in Crossref: 165] [Cited by in F6Publishing: 136] [Article Influence: 82.5] [Reference Citation Analysis]
122 Gong J, Tuli R, Shinde A, Hendifar AE. Meta-analyses of treatment standards for pancreatic cancer. Mol Clin Oncol 2016;4:315-25. [PMID: 26998283 DOI: 10.3892/mco.2015.716] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
123 Coveler AL, Herman JM, Simeone DM, Chiorean EG. Localized Pancreatic Cancer: Multidisciplinary Management. Am Soc Clin Oncol Educ Book 2016;35:e217-26. [PMID: 27249726 DOI: 10.1200/EDBK_160827] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
124 Reyngold M, Winter KA, Regine WF, Abrams RA, Safran H, Hoffman JP, Mowat RB, Hayes JP, Kessel IL, DiPetrillo T, Narayan S, Chen Y, Ben-Josef E, Delouya G, Suh JH, Meyer J, Haddock MG, Feldman M, Gaur R, Yost K, Peterson RA, Sherr DL, Moughan J, Crane CH. Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704. Oncologist 2020;25:e477-83. [PMID: 32162826 DOI: 10.1634/theoncologist.2019-0562] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
125 Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529-3545. [PMID: 26185420 DOI: 10.2147/DDDT.S60328] [Cited by in Crossref: 74] [Cited by in F6Publishing: 44] [Article Influence: 12.3] [Reference Citation Analysis]
126 Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, Thayer SP, Lauwers GY, Deshpande V, Mino-Kenudson M. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012;152:S43-S49. [PMID: 22763261 DOI: 10.1016/j.surg.2012.05.020] [Cited by in Crossref: 136] [Cited by in F6Publishing: 120] [Article Influence: 15.1] [Reference Citation Analysis]
127 Reese AS, Lu W, Regine WF. Utilization of intensity-modulated radiation therapy and image-guided radiation therapy in pancreatic cancer: is it beneficial? Semin Radiat Oncol 2014;24:132-9. [PMID: 24635870 DOI: 10.1016/j.semradonc.2013.11.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
128 Kasikci E, Aydemir E, Yogurtcu BM, Sahin F, Bayrak OF. Repurposing of Alexidine Dihydrochloride as an Apoptosis Initiator and Cell Cycle Inhibitor in Human Pancreatic Cancer. Anticancer Agents Med Chem 2020;20:1956-65. [PMID: 32384037 DOI: 10.2174/1871520620666200508085439] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022. [PMID: 27158978 DOI: 10.1038/nrdp.2016.22] [Cited by in Crossref: 657] [Cited by in F6Publishing: 552] [Article Influence: 131.4] [Reference Citation Analysis]
130 Berlin JD, Feng Y, Catalano P, Abbruzzese JL, Philip PA, McWilliams RR, Lowy AM, Benson AB III, Blackstock AW. An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). Oncology 2018;94:39-46. [PMID: 29040974 DOI: 10.1159/000480295] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
131 Mellon EA, Springett GM, Hoffe SE, Hodul P, Malafa MP, Meredith KL, Fulp WJ, Zhao X, Shridhar R. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Cancer. 2014;120:1171-1177. [PMID: 24390779 DOI: 10.1002/cncr.28543] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
132 Kagedan DJ, Raju RS, Dixon ME, Shin E, Li Q, Liu N, Elmi M, El-Sedfy A, Paszat L, Kiss A, Earle CC, Mittmann N, Coburn NG. The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. HPB (Oxford) 2016;18:339-47. [PMID: 27037203 DOI: 10.1016/j.hpb.2015.12.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
133 Parashar B, Chen WC, Herman JM, Potters L. Disease Site-Specific Guidelines for Curative Radiation Treatment During 'Limited Surgery' and 'Hospital Avoidance': A Radiation Oncology Perspective From the Epicenter of COVID-19 Pandemic. Cureus 2020;12:e8190. [PMID: 32440386 DOI: 10.7759/cureus.8190] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
134 Hashmi A, Kozick Z, Fluck M, Hunsinger MA, Wild J, Arora TK, Shabahang MM, Blansfield JA. Neoadjuvant versus Adjuvant Chemotherapy for Resectable Pancreatic Adenocarcinoma: A National Cancer Database Analysis. The American Surgeon 2018;84:1439-45. [DOI: 10.1177/000313481808400946] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
135 Huart C, Chen JW, Le Calvé B, Michiels C, Wéra AC. Could Protons and Carbon Ions Be the Silver Bullets Against Pancreatic Cancer? Int J Mol Sci 2020;21:E4767. [PMID: 32635552 DOI: 10.3390/ijms21134767] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
136 Shaib WL, Jones JS, Goodman M, Sarmiento JM, Maithel SK, Cardona K, Kane S, Wu C, Alese OB, El-Rayes BF. Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. Oncologist 2018;23:704-11. [PMID: 29445028 DOI: 10.1634/theoncologist.2017-0487] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
137 White RR, Lowy AM. Clinical Management: Resectable Disease. Cancer J 2017;23:343-9. [PMID: 29189330 DOI: 10.1097/PPO.0000000000000291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
138 Kamarajah SK, Bundred JR, Alrawashdeh W, Manas D, White SA. A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC).HPB (Oxford). 2020;22:649-659. [PMID: 31894014 DOI: 10.1016/j.hpb.2019.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
139 Topkan E, Parlak C, Yapar F. Impact of omission of elective nodal irradiation on treatment outcomes in locally advanced pancreatic adenocarcinoma patients treated with definitive concurrent chemoradiotherapy. Pancreatology 2012;12:434-9. [DOI: 10.1016/j.pan.2012.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
140 Goel N, Reddy SS. Randomized Clinical Trials in Pancreatic Cancer. Surg Oncol Clin N Am 2017;26:767-90. [PMID: 28923230 DOI: 10.1016/j.soc.2017.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
141 Silvestris N, Brunetti O, Bittoni A, Cataldo I, Corsi D, Crippa S, D'Onofrio M, Fiore M, Giommoni E, Milella M, Pezzilli R, Vasile E, Reni M. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). Cancers (Basel) 2020;12:E1681. [PMID: 32599886 DOI: 10.3390/cancers12061681] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
142 Zhu X, Li F, Ju X, Cao F, Cao Y, Fang F, Qing S, Shen Y, Jia Z, Zhang H. Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer. Cancer Med 2017;6:2263-70. [PMID: 28834410 DOI: 10.1002/cam4.1164] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
143 Pen SL, Shan YS, Hsiao CF, Liu TW, Chen JS, Ho CL, Chou WC, Hsieh RK, Chen LT, Ch'ang HJ. High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial. Radiother Oncol 2021;158:146-54. [PMID: 33667587 DOI: 10.1016/j.radonc.2021.02.037] [Reference Citation Analysis]
144 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.3322/caac.21190] [Cited by in Crossref: 479] [Cited by in F6Publishing: 436] [Article Influence: 59.9] [Reference Citation Analysis]
145 You MS, Ryu JK, Huh G, Chun JW, Paik WH, Lee SH, Kim YT. Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach. World J Clin Oncol 2020;11:747-60. [PMID: 33033696 DOI: 10.5306/wjco.v11.i9.747] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
146 Xia Z, Jia X, Chen K, Li D, Xie J, Xu H, Mao Y. Survival benefits from postoperative radiation therapy on lymph node positive patients with pancreatic adenocarcinoma. Oncotarget 2016;7:46646-52. [PMID: 27244891 DOI: 10.18632/oncotarget.9620] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Herman JM, Jabbour SK, Lin SH, Deek MP, Hsu CC, Fishman EK, Kim S, Cameron JL, Chekmareva M, Laheru DA, Narang AK, Pawlik TM, Hruban RH, Wolfgang CL, Iacobuzio-Donahue CA. Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 2018;47:208-12. [PMID: 29329157 DOI: 10.1097/MPA.0000000000000985] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
148 Yabar CS, Winter JM. Pancreatic Cancer: A Review. Gastroenterol Clin North Am. 2016;45:429-445. [PMID: 27546841 DOI: 10.1016/j.gtc.2016.04.003] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 12.8] [Reference Citation Analysis]
149 Sutton JM, Abbott DE. Neoadjuvant therapy for pancreas cancer: past lessons and future therapies. World J Gastroenterol. 2014;20:15564-15579. [PMID: 25400440 DOI: 10.3748/wjg.v20.i42.15564] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
150 Rodrigues V, Dopazo C, Pando E, Blanco L, Caralt M, Gómez-Gavara C, Bilbao I, Salcedo MT, Balsells J, Charco R. Is the involvement of the hepatic artery lymph node a poor prognostic factor in pancreatic adenocarcinoma? Cir Esp (Engl Ed) 2020;98:204-11. [PMID: 31839175 DOI: 10.1016/j.ciresp.2019.09.015] [Reference Citation Analysis]
151 Delpero JR, Boher JM, Sauvanet A, Le Treut YP, Sa-Cunha A, Mabrut JY, Chiche L, Turrini O, Bachellier P, Paye F. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? Ann Surg Oncol. 2015;22:1874-1883. [PMID: 25665947 DOI: 10.1245/s10434-014-4304-3] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 10.7] [Reference Citation Analysis]
152 Fogel EL, Shahda S, Sandrasegaran K, DeWitt J, Easler JJ, Agarwal DM, Eagleson M, Zyromski NJ, House MG, Ellsworth S, El Hajj I, O'Neil BH, Nakeeb A, Sherman S. A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. Am J Gastroenterol. 2017;112:537-554. [PMID: 28139655 DOI: 10.1038/ajg.2016.610] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 14.5] [Reference Citation Analysis]
153 Huang X, Ding L, Liu X, Tong R, Ding J, Qian Z, Cai L, Zhang P, Li D. Regulation of tumor microenvironment for pancreatic cancer therapy. Biomaterials 2021;270:120680. [PMID: 33588140 DOI: 10.1016/j.biomaterials.2021.120680] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
154 Chang YR, Han SS, Park SJ, Lee SD, Yoo TS, Kim YK, Kim TH, Woo SM, Lee WJ, Hong EK. Surgical outcome of pancreatic cancer using radical antegrade modular pancreatosplenectomy procedure. World J Gastroenterol. 2012;18:5595-5600. [PMID: 23112553 DOI: 10.3748/wjg.v18.i39.5595] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
155 Sakaguchi T, Satoi S, Yamamoto T, Yamaki S, Sekimoto M. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma. Surg Today 2020;50:335-43. [PMID: 31993761 DOI: 10.1007/s00595-020-01963-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
156 Abrams RA. Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful? Expert Review of Gastroenterology & Hepatology 2014;6:149-61. [DOI: 10.1586/egh.12.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
157 Perez K, Clancy TE, Mancias JD, Rosenthal MH, Wolpin BM. When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma. J Clin Oncol 2017;35:485-9. [PMID: 28029328 DOI: 10.1200/JCO.2016.70.2134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
158 O'Kane GM, Ladak F, Gallinger S. Advances in the management of pancreatic ductal adenocarcinoma. CMAJ 2021;193:E844-51. [PMID: 34099468 DOI: 10.1503/cmaj.201450] [Reference Citation Analysis]
159 Bradley A, Van Der Meer R. Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis. PLoS One 2019;14:e0212805. [PMID: 30817807 DOI: 10.1371/journal.pone.0212805] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
160 Bernard ME, Sutera PA, Iarrobino NA, Quan K, Burton SA, Bahary N, Hogg M, Zureikat A, Heron DE. Initial Results of a Prospective Study of Adjuvant Pancreatic Stereotactic Body Radiation Therapy for Close or Positive Margins. Adv Radiat Oncol 2019;4:294-301. [PMID: 31011674 DOI: 10.1016/j.adro.2018.11.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
161 Mehtsun WT, Hashimoto DA, Ferrone CR. Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma. Advances in Surgery 2019;53:253-69. [DOI: 10.1016/j.yasu.2019.04.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
162 Abrams MJ, Rakszawski K, Vasekar M, Passero F, Abbas A, Jia Y, Saif MW. Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology. Therap Adv Gastroenterol 2016;9:141-51. [PMID: 26929776 DOI: 10.1177/1756283X15622601] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
163 Cho M, Wang-Gillam A, Myerson R, Gao F, Strasberg S, Picus J, Sorscher S, Fournier C, Nagaraj G, Parikh P, Suresh R, Linehan D, Tan BR. A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma. HPB (Oxford) 2015;17:587-93. [PMID: 25800066 DOI: 10.1111/hpb.12413] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
164 Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci 2019;20:E4543. [PMID: 31540286 DOI: 10.3390/ijms20184543] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
165 Calvo F, Guillen Ponce C, Muñoz Beltran M, Sanjuanbenito Dehesa A. Multidisciplinary management of locally advanced–borderline resectable adenocarcinoma of the head of the pancreas. Clin Transl Oncol 2013;15:173-81. [DOI: 10.1007/s12094-012-0962-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
166 Tatarian T, Jiang W, Leiby BE, Grigoli A, Jimbo M, Dabbish N, Neoptolemos JP, Greenhalf W, Costello E, Ghaneh P, Halloran C, Palmer D, Buchler M, Yeo CJ, Winter JM, Brody JR. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. Ann Surg. 2018;267:364-369. [PMID: 27893535 DOI: 10.1097/sla.0000000000002088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
167 Lutsyk M, Ben-Yosef R. The Role of Radiotherapy in Resected R0/R+ Pancreatic Cancer: A Real-Life Single-Institution Experience. Am J Clin Oncol 2020;43:187-92. [PMID: 31842116 DOI: 10.1097/COC.0000000000000653] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
168 Blaszak M, El-Masri M, Hirmiz K, Mathews J, Omar A, Elfiki T, Gupta R, Hamm C, Kanjeekal S, Kay A, Kulkarni S, Ghafoor A. Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study. Mol Clin Oncol 2017;6:583-8. [PMID: 28413673 DOI: 10.3892/mco.2017.1179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
169 Parekh HD, Starr J, George TJ Jr. The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. Curr Treat Options Oncol 2017;18:73. [PMID: 29143898 DOI: 10.1007/s11864-017-0515-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]